地诺单抗是一种什么药物？

What kind of drug is denosumab? Denosumab (Denosumab) is a monoclonal antibody targeting RANKL that can reduce skeletal-related events related to bone lesions or metastasis in patients with advanced solid tumors, and its anti-bone metastasis effect is significantly better than traditional bisphosphonate drugs.

Clinical data show that compared with zoledronic acid, denosumab prolongs the time to the first adverse bone event (ARE) in patients by 17%, or significantly delays the median time to the first bone-related event (SRE) by 8.2 months (27.6 months vs. 19.4 months). months), denosumab also prolonged the time interval between the first episode and the recurrence of SRE by 18% in the study; in addition, for patients with mild or no pain at study entry, denosumab also significantly prolonged the time between pain exacerbation compared with zoledronic acid.

Denosumab (Denosumab) mainly treats: (1) Preventing bone-related symptoms in patients with bone metastases from solid tumors. (2) Treat patients with giant cell tumors of bone who are not suitable for surgery and have mature skeletal systems. (3) Treatment of malignant hypercalcemia that is resistant to bisphosphonates. (4) For refractory malignant hypercalcemia that is insensitive to bisphosphonate drugs. (5) Restricted use: Not used to treat and prevent bone-related symptoms in patients with multiple myeloma.

Denosumab (Denosumab) can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion, or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

The above is the drug introduction (Denosumab) provided to you by our Medical Companion Travel Overseas Medical Consulting Service Company.

Recommended related hot articles: /newsDetail/74079.html